Soluble urokinase plasminogen activator receptor as a long-term prognostic biomarker in acute coronary syndromes

Peiró, Óscar M.; Cediel, Germán; Bonet, Gil; Rojas, Sergio; Quintern, Verónica; Carrasquer, Anna; González‐Del‐Hoyo, Maribel; Sanz, E; Bardajı́, Alfredo

doi:10.1080/1354750x.2020.1778090

Cited by 6 publications

(7 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Eight studies provided all‐cause mortality rates. 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 The degree of heterogeneity for this outcome was found to be very high (I 2 = 96.0%; p = 0.000). When comparing patients in the highest and lowest suPAR categories, the pooled HR for all‐cause mortality was 2.24 (95% CI 1.97–2.55).…”

Section: Resultsmentioning

confidence: 87%

“…Eight studies provided all‐cause mortality rates 10–17 . The degree of heterogeneity for this outcome was found to be very high (I 2 = 96.0%; p = 0.000).…”

Section: Resultsmentioning

confidence: 99%

“…OMCE incidence was reported as a study endpoint in three studies 11,13,15 . Fixed‐effects modelling showed that there was no substantial heterogeneity across these trials (I 2 = 9.8%; p = 0.330).…”

Section: Resultsmentioning

confidence: 99%

“…From the original pool of 208 papers discovered via the literature search, only 29 were considered worthy of a full‐text read and 9 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 were finally included in this meta‐analysis. All studies were considered of high quality, with NOS scores of six stars or higher.…”

Section: Resultsmentioning

confidence: 99%

See 3 more Smart Citations

Prognostic value of soluble urokinase‐type plasminogen activator receptor in coronary artery disease: A meta‐analysis

Ding

Yu-hong

et al. 2022

Eur J Clin Investigation

View full text Add to dashboard Cite

Background A potential inflammatory biomarker, soluble urokinase‐type plasminogen activator receptor (suPAR) has been utilized to assist the prognostic assessment of coronary artery disease (CAD) patients; however, outcomes have been inconsistent. The prognostic relevance of suPAR as a predictor of CAD patient adverse outcomes was therefore examined. Methods Research articles published as of 1 January 2022 were retrieved from PubMed, Embase, the Web of Science and the Cochrane Library. All‐cause mortality, cardiovascular mortality and other major cardiovascular events (nonfatal myocardial infarction, heart failure or stroke) were analysed as a subset of relevant studies' results. We calculated hazard ratios (HRs) and 95% confidence intervals (CIs) for each study. The broad EQUATOR guidelines were conformed. Risk of bias was assessed with ROBINS‐I tool. Results In total, this analysis included nine studies including 14,738 CAD patients. All included studies made a correction for certain potential confounders. However, risk of bias ranged from moderate to critical. When the ROBINS‐I tool was used. Patients with CAD that exhibited increased suPAR levels had a substantially higher risk of all‐cause mortality (HR = 2.24; 95% CI 1.97–2.55) or cardiovascular mortality (HR = 2.02; 95% CI 1.58–2.58), but not of developing other major cardiovascular events (HR = 1.63; 95% CI 0.86–3.11). Considerable heterogeneity across studies was observed in our meta‐analyses, but no significant publication bias was detected. Conclusion In patients with coronary disease, suPAR may have prognostic value for both all‐cause and cardiovascular mortality but not for other major cardiovascular events.

show abstract

Section: Resultsmentioning

confidence: 87%

“…Eight studies provided all‐cause mortality rates 10–17 . The degree of heterogeneity for this outcome was found to be very high (I 2 = 96.0%; p = 0.000).…”

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Prognostic value of soluble urokinase‐type plasminogen activator receptor in coronary artery disease: A meta‐analysis

Ding

Yu-hong

et al. 2022

Eur J Clin Investigation

View full text Add to dashboard Cite

show abstract

“…Furthermore, levels were elevated in patients with COVID-19 and sepsis likely due to the increased activity of immune cells. We can only speculate that the burden of inflammation and in parallel, the levels of suPAR are lower in patients with intoxication and acute myocardial infarction when compared to patients with sepsis 32,33 .…”

Section: Discussionmentioning

confidence: 88%

Soluble urokinase plasminogen activator receptor (suPAR) predicts critical illness and kidney failure in patients admitted to the intensive care unit

Reisinger

Niedrist

Posch

et al. 2021

Sci Rep

View full text Add to dashboard Cite

Soluble urokinase plasminogen activator receptor (suPAR) is an inflammatory biomarker and risk factor for kidney diseases, with a potential prognostic value in critically ill patients. In this monocentric prospective study, we measured plasma suPAR levels immediately after ICU admission in unselected 237 consecutive patients using a turbidimetric assay. Primary objective was the prognostic value for ICU- and 28-day mortality. Secondary objectives were association with sequential organ failure assessment (SOFA) score, coagulation and inflammation markers, AKI-3 and differences in prespecified subgroups. Median suPAR levels were 8.0 ng/mL [25th-75th percentile 4.3–14.4], with lower levels in ICU survivors than non-survivors (6.7 vs. 11.6 ng/mL, p < 0.001). SuPAR levels were higher in COVID-19, kidney disease, moderate-to-severe liver disease, and sepsis. ICU mortality increased by an odds ratio (OR) of 4.7 in patients with the highest compared to lowest quartile suPAR. Kaplan–Meier overall survival estimates at 3 months were 63% and 49%, in patients with suPAR below/above 12 ng/mL (log-rank p = 0.027). Due to an observed interaction between SOFA score and suPAR, we performed a random forest method identifying cutoffs. ICU mortality was 53%, 17% and 2% in patients with a SOFA score > 7, SOFA ≤ 7 & suPAR > 8 ng/mL, and SOFA score ≤ 7 & suPAR ≤ 8 ng/mL, respectively. suPAR was a significant predictor for AKI-3 occurrence (OR per doubling 1.89, 95% CI: 1.20–2.98; p = 0.006). suPAR levels at ICU admission may offer additional value for risk stratification especially in ICU patients with moderate organ dysfunction as reflected by a SOFA score ≤ 7.

show abstract

SEPSIGN: early identification of sepsis signs in emergency department

Lafon,

Cazalis,

Hart

et al. 2024

Intern Emerg Med

View full text Add to dashboard Cite

Soluble urokinase plasminogen activator receptor as a long-term prognostic biomarker in acute coronary syndromes

Abstract: Primary endpointEvents: 16 deaths; suPAR <2.6ng/mL: 3 (1.5%) and suPAR ≥2.6ng/mL: 13 (8.9%).Unadjusted suPAR HR 5.9; 95% CI 1.7-20.8; p=0.005.

Cited by 6 publications

References 28 publications

Prognostic value of soluble urokinase‐type plasminogen activator receptor in coronary artery disease: A meta‐analysis

Prognostic value of soluble urokinase‐type plasminogen activator receptor in coronary artery disease: A meta‐analysis

Soluble urokinase plasminogen activator receptor (suPAR) predicts critical illness and kidney failure in patients admitted to the intensive care unit

SEPSIGN: early identification of sepsis signs in emergency department

Contact Info

Product

Resources

About